Trial · NCT01263496
Results by group295
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 295
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events. | Alogliptin 6.25 mg QD | Serious Adverse Event | 1 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD | Serious Adverse Event | 5 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD | Serious Adverse Event | 8 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 50 mg QD | Serious Adverse Event | 5 | participants | |
| Number of Participants With Adverse Events. | Voglibose 0.2 mg TID | Serious Adverse Event | 4 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 6.25 mg QD | Serious Adverse Event Related to Study Drug | 1 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD | Serious Adverse Event Related to Study Drug | 2 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD | Serious Adverse Event Related to Study Drug | 2 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 50 mg QD | Serious Adverse Event Related to Study Drug | 2 | participants | |
| Number of Participants With Adverse Events. | Voglibose 0.2 mg TID | Serious Adverse Event Related to Study Drug | 0 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 6.25 mg QD | Other Adverse Events (Incidence ≥3%) | 78 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD | Other Adverse Events (Incidence ≥3%) | 81 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD | Other Adverse Events (Incidence ≥3%) | 81 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 50 mg QD | Other Adverse Events (Incidence ≥3%) | 88 | participants | |
| Number of Participants With Adverse Events. | Voglibose 0.2 mg TID | Other Adverse Events (Incidence ≥3%) | 74 | participants | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 6.25 mg QD | -0.55 | Standard Deviation 0.703 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 12.5 mg QD | -0.70 | Standard Deviation 0.545 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 25 mg QD | -0.74 | Standard Deviation 0.520 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 50 mg QD | -0.86 | Standard Deviation 0.499 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Voglibose 0.2 mg TID | -0.15 | Standard Deviation 0.735 | percentage of Glycosylated Hemoglobin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263496/results